Allworth Financial LP Increases Position in Novo Nordisk A/S $NVO

Allworth Financial LP grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 258.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 131,741 shares of the company’s stock after buying an additional 95,033 shares during the period. Allworth Financial LP’s holdings in Novo Nordisk A/S were worth $6,703,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC raised its holdings in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. raised its holdings in Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL purchased a new position in Novo Nordisk A/S during the second quarter worth about $314,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Novo Nordisk A/S Stock Down 2.4%

Shares of NYSE NVO opened at $44.71 on Friday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm’s 50 day moving average price is $39.73 and its 200 day moving average price is $46.69. The firm has a market cap of $199.63 billion, a P/E ratio of 10.50, a price-to-earnings-growth ratio of 4.08 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NVO has been the subject of several analyst reports. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.